In the fight against pancreatic cancer, a combination of drugs outperformed other treatments in human cell and mouse models, and should be used in human clinical trials, UC San Diego researchers announced Wednesday.
Mutations in the KRAS gene are the major driver of pancreatic cancer. The resulting protein controls multiple signaling pathways involved in cell growth and survival. In cancer, the gene is mutated to be permanently "on," driving cells to excessively multiply and form tumors.